| Bioactivity | BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC)[1]. |
| In Vivo | BNT411 (3 mg/kg; 静脉注射; 每隔 4 到 5 天一次，共注射 8 次 ) 在小鼠肿瘤模型中具有抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 2296821-50-4 |
| Formula | C24H33N5O3 |
| Molar Mass | 439.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ugur Sahin, et al. Tlr7 agonist and combinations for cancer treatment. WIPO. WO2023083868. 2023-05-19 |